Compare Paycom Software Inc (PAYC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs Twist Bioscience Corp — how do they compare? Paycom Software Inc trades at $214.7 (market cap $9.88B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Paycom Software Inc is the larger of the two by market cap, and Paycom Software Inc pays a 0.68% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| PAYC | TWST | |
|---|---|---|
Market Cap | $9.88B | $8.42B |
Sector | Technology | Health |
52-Week High | $240.52 | $153.10 |
52-Week Low | $113.59 | $24.16 |
Enterprise Value | $10.66B | $8.35B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $219.16, down 5.4% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal despite recent weakness, supported by positive analyst sentiment and institutional accumulation. Recent Q2 2026 results exceeded expectations with EPS of $2.78 beating estimates of $2.38, driving management's raised full-year guidance.
Outlook remains positive with a consensus price target of $231.70 offering 5.7% upside potential. Key opportunities include sustained revenue growth and expanding margins, while risks involve competitive pressures and market volatility. The company's strong cash flow generation and shareholder returns through dividends and buybacks support long-term value creation.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
